Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It has an agreement with Celerity Pharmaceuticals, LLC to develop acute care generic injectable premix and oncolytic products. The company operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Baxter International Inc.

The latest announcement is out from Baxter International ( ($BAX) ). Effective for the quarter ended June 30, 2026, Baxter International reorganize...

Baxter International Updates Segment Reporting Structure and Metrics

Citi analyst Joanne Wuensch maintained a Sell rating on Baxter International on July 6 and set a price target of $17.00. The company’s shares close...

Citi Sticks to Its Sell Rating for Baxter International (BAX)

In a report released on July 3, Anke Reingen from RBC Capital maintained a Buy rating on Julius Baer Group Ltd, with a price target of CHF72.00. Th...

RBC Capital Reaffirms Their Buy Rating on Julius Baer Group Ltd (BAER)

Morgan Stanley analyst Giulia Miotto maintained a Sell rating on Julius Baer Group Ltd today and set a price target of CHF66.00. According to TipRa...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BAX	$22.40	+3.37%	4.98M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BAX	$22.40	+3.4%	4.98M
3
4
5
6

BAX

BAX

Get Baxter International Inc. Data in Excel

Get Baxter International Inc. Data in Excel